What’s Ahead for Aradigm Corporation (NASDAQ:ARDM) After Less Shorted Shares?

April 18, 2018 - By Marguerite Chambers

Investors sentiment increased to 3 in 2017 Q4. Its up 2.14, from 0.86 in 2017Q3. It is positive, as 2 investors sold Aradigm Corporation shares while 1 reduced holdings. 5 funds opened positions while 4 raised stakes. 4.54 million shares or 4.27% more from 4.35 million shares in 2017Q3 were reported.
Fmr holds 0% or 168,740 shares in its portfolio. Tower Rech Capital (Trc) reported 0% in Aradigm Corporation (NASDAQ:ARDM). Evercore Wealth Ltd Co has invested 0% in Aradigm Corporation (NASDAQ:ARDM). Spark Management Ltd Liability has 13,000 shares. 7 were accumulated by Deutsche Natl Bank Ag. First Eagle Management Lc holds 0.06% or 3.85M shares. Focused Wealth Incorporated accumulated 2 shares. Vanguard owns 361,998 shares or 0% of their US portfolio. Northern holds 0% in Aradigm Corporation (NASDAQ:ARDM) or 25,701 shares. Morgan Stanley owns 18,216 shares for 0% of their portfolio. Geode Lc accumulated 0% or 63,010 shares. Blackrock Incorporated reported 0% of its portfolio in Aradigm Corporation (NASDAQ:ARDM). Royal Bank Of Canada accumulated 507 shares or 0% of the stock. State Bank Of Ny Mellon Corp owns 22,220 shares.

Since January 29, 2018, it had 0 insider purchases, and 1 sale for $26,027 activity.

The stock of Aradigm Corporation (NASDAQ:ARDM) registered a decrease of 5.18% in short interest. ARDM’s total short interest was 642,300 shares in April as published by FINRA. Its down 5.18% from 677,400 shares, reported previously. With 68,300 shares average volume, it will take short sellers 9 days to cover their ARDM’s short positions. The short interest to Aradigm Corporation’s float is 9.07%.

The stock decreased 1.05% or $0.02 during the last trading session, reaching $1.89. About 131,525 shares traded. Aradigm Corporation (NASDAQ:ARDM) has declined 25.73% since April 18, 2017 and is downtrending. It has underperformed by 37.28% the S&P500.

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. The company has market cap of $27.51 million. The companyÂ’s lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. It currently has negative earnings. It is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, as well as the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever, and inhaled anthrax.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.